COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/018501

A. CLASSIFIC Int.Cl	CATION OF SUBJECT MATTER CO7K16/28, C12N15/11, 1/15, 1 A61K39/395, A61P35/00, 35/02,		
According to Int	ernational Patent Classification (IPC) or to both nationa	l classification and IPC	
B. FIELDS SE	ARCHED		
Minimum docun	nentation searched (classification system followed by cl CO7K16/28, C12N15/11, 1/15, 1 A61K39/395, A61P35/00, 35/02	1/19, 1/21, 5/00, Cl2P21	
Documentation s	searched other than minimum documentation to the exte	nt that such documents are included in the	fields searched
.CAPlus	pase consulted during the international search (name of of (STN), MEDLINE (STN), BIOSIS (STN rot/PIR/GeneSeq, Genbank/EMBL/E), WPIDS(STN), JICST FI	
C. DOCUMEN	ITS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
P,X	BRUENKE J. et al., "A recombi single-chain Fv antibody agai II and FcYRIII (CD16) trigger of lymphoma cells", British J Haematology, April 2004, Vol. pages 167 to 179	nst HLA class s effective lysis fournal of	1-7,17-28
Y	SEKIMOTO E. et al., "A recomb I-Specific Single Fv Diabody Death in Human Lymphoid Malic Blood, November, 2003, Vol.10 page 933a, Abstract. #3474	Induces Cell	1-14,16-28
× Further do	cuments are listed in the continuation of Box C.	See patent family annex.	
"A" document d to be of part "E" earlier appli filing date "L" document w cited to esta special rease "O" document re "P" document pr priority date	gories of cited documents: efining the general state of the art which is not considered icular relevance cation or patent but published on or after the international which may throw doubts on priority claim(s) or which is ablish the publication date of another citation or other on (as specified) ferring to an oral disclosure, use, exhibition or other means ablished prior to the international filing date but later than the claimed 11 completion of the international search ch, 2005 (11.03.05)	"T" later document published after the interdate and not in conflict with the application the principle or theory underlying the in "X" document of particular relevance; the classifier of novel or cannot be considered novel or cannot be considered to involve an inventive significant with one or more other such a being obvious to a person skilled in the "&" document member of the same patent for the same patent for mailing of the international search 29 March, 2005 (29.	tion but cited to understand vention aimed invention cannot be cred to involve an inventive aimed invention cannot be tep when the document is documents, such combination art the combination are the combina
Japanes	g address of the ISA/ se Patent Office	Authorized officer	
Facsimile No.		Telephone No.	

Form PCT/ISA/210 (second sheet) (January 2004)

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/018501

		PC1/0F2	004/018501
C (Continuation).	DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
Y	KIPRIYANOV SM. et al., "Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies", J.Mol.Biol., 2003, June, Vol.330, No.1, pages 99 to 111		1-14,16-28
Y	Laurent Genestier, et al., "Fas-Independe Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I 1 Domain", Blood, 1997, Vol.90, No.9, pages 3629 to	7	1-7,17-28
Υ	Hudson PJ. et al., "High avidity scFv multimers: diabodies and triabodies.", J.Immunol.Methods., 1999, Vol.231, No. 1-p.177-89., Review	-2,	1-7,17-28
. Υ	JP 7-503622 A (The Dow Chemical Co.), 20 April, 1995 (20.04.95), Full description & WO 94/13806 A1 & EP 628078 A & US 5877291 A1		1-7,17-28
Y	CO MS., et al., "A humanized antibody specific for the platelet integrin gpIIb/IIIa." J.Immunol., 1994, Vol.152, No.6, p.2968-76.		1-14,16-28
P, A	WO 2004/033499 Al (Chugai Pharmaceutical Co., Ltd.), 22 April, 2004 (22.04.04), (Family: none)		1-28
			. (
		,	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)